AIM : The study aimed to nd the link between the fat deposition in pancreas and liver and metabolic syndrome. METHODOLOGY : It was a cross sectional study . 50 patients with ultrasonographic evidence of fatty pancreas were included and were evaluated for the presence of fatty liver on ultrasonography and were assessed for the presence of metabolic syndrome. RESULTS: Metabolic syndrome was detected in 62% of patients of Non alcoholic fatty pancreas disease (NAFPD). The overall prevalence of fatty liver was 72% in patients with NAFPD. The presence of fatty liver in the studied patients increased the number of parameters of metabolic syndrome. It was statistically signicant (p=0.043). CONCLUSION: NAFPD is closely related to metabolic syndrome and fatty liver
Background: Coronary artery disease (CAD) is major cause of death and mortality in the developed world. Coronary atherosclerotic disease involves the epicardial coronary arteries and may manifest as an acute or chronic coronary syndrome. Acute coronary syndrome (ACS) arises from atherosclerotic plaque rupture leading to coronary thrombosis and/or spasm.Methods: The present study was conducted in department of medicine, Guru Nanak Dev hospital attached to government medical college, Amritsar from May 2021 to December 2021. This was a prospective observational study in which a total of 50 patients of ACS were enrolled. Serum albumin levels of the patients were recorded and clinical outcomes based on the albumin levels were compared between the patients.Results: The patients with low serum albumin levels had worse outcomes. The mean serum albumin level of STEMI and NSTEMI patients in hypoalbuminemia group was 2.88±0.11 g/dl and 3.15±0.26 g/dl (p=0.047). The mean serum albumin level of patients having mortality in hypoalbuminemia group was 2.87±0.06 g/dl and those who didn’t have mortality was 3.19±0.21 g/dl (p=0.013). The mean serum albumin level of patients developing new onset heart failure in hypoalbuminemia group was 2.85±0.06 g/dl and those not developing had 3.11±0.19 g/dl (p=0.021).Conclusions: We conclude that ACS patients presenting with hypoalbuminemia are more likely to develop worse outcomes in the form of heart failure, cardiogenic shock and mortality. ACS patients presenting with low serum albumin levels have more chances of developing STEMI.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.